Efficacy of Photodynamic Therapy with Chlorine-Based Photosensitizer in the Treatment of Basal Cell Carcinomas
DOI:
https://doi.org/10.30683/1927-7229.2023.12.03Keywords:
Basal cell carcinoma, chlorine-based photosensitizer, photodynamic therapy, tolerability, safety and antitumor efficacyAbstract
The aim of this study is to evaluate a safety and antitumor efficacy of photodynamic therapy (PDT) with chlorine-based photosensitizer (PS) for treatment patients with basal cell skin carcinomas (BCC).
Material and Methods: The work was performed on the basis of the Department of hyperthermia and photodynamic therapy. The object of the study were 172 patients with a verified diagnosis of BCC (T1N0M0, I stage), who received treatment from 2007 to 2022. PS «Photolon» (RUE «Belmedpreparaty», Republic of Belarus) was administrated intravenously at a dose of 2.0-2.5 mg/kg. The session of PDT was performed 2.5-3 h after intravenous injection of PS using semiconductor lasers (λ=660±5 nm) with exposure doses 50-250 J/cm² and power density – 0.15-0.5 W/cm². Frequency and severity of side effects after treatment session was assessed based on the criteria CTCAE (Version 4.03; 2010). The antitumor efficacy was evaluated 3 months after treatment. Clinical outcome was evaluated visually and morphologically by cytological or histopathological examination. Performance criteria were as follows (according to WHO, 1979).
Results: The phenomenon of skin phototoxicity due to violation of the light regime (hyperemia, burning, slight swelling of the soft tissues of the face; CTCAE, I-II grades) was registered in 5.8% of cases (n=10). Serious adverse reactions (anaphylactic shock, Quincke's edema, severe pain syndrome) after the administration of PS and photoirradiation were not identified. Complete and partial regressions of tumors was observed in 93.0% and 4.7% of patients, respectively. The objective answer was 97.7%. The frequency of local relapses of the disease 1, 2, 3, 4 and 5 years after PDT was 3.1%, 3.1%, 4.6%, 4.6% and 6.9%, respectively.
Сonclusion: PDT is a well-tolerated and highly effective therapeutic option in patients with BCC.
References
Dika E, Scarfì F, Ferracin M, et al. Basal cell carcinoma: a comprehensive review. Int J Mol Sci 2020; 21(15): 5572. https://doi.org/10.3390/ijms21155572 DOI: https://doi.org/10.3390/ijms21155572
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-80. https://doi.org/10.1111/j.1365-2133.2012.10830.x DOI: https://doi.org/10.1111/j.1365-2133.2012.10830.x
Tzerkovsky DA. Photodynamic therapy for patients with basal cell carcinoma: N.N. Alexandrov national cancer center experience. Arch Gen Intern Med 2017; 1: 22-4.
Basset-Segun N, Herms F. Update on the management of basal cell carcinoma. Acta Derm Venereol 2020; 100(11): 5750. https://doi.org/10.2340/00015555-3495 DOI: https://doi.org/10.2340/00015555-3495
Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol 2007; 56(1): 91-5. https://doi.org/10.1016/j.jaad.2006.07.007 DOI: https://doi.org/10.1016/j.jaad.2006.07.007
Kim SE, Lee KS, Cho JE. Photodynamic therapy combined with cryotherapy for the treatment of nodular basal cell carcinoma. Oncol Lett 2013; 6: 939-41. https://doi.org/10.3892/ol.2013.1504 DOI: https://doi.org/10.3892/ol.2013.1504
Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA: A Cancer J Clin 2011; 61: 250-81. https://doi.org/10.3322/caac.20114 DOI: https://doi.org/10.3322/caac.20114
Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy – mechanisms, photosensitizers and combinations. Biomed Pharmacother 2018; 106: 1098-107. https://doi.org/10.1016/j.biopha.2018.07.049 DOI: https://doi.org/10.1016/j.biopha.2018.07.049
Wang BC, Fu C, Qin L, et al. Photodynamic therapy with methyl-5-aminolevulinate for basal cell carcinoma: A systematic review and meta-analysis. Photodiagnosis Photodyn Ther 2020; 29: 101667. https://doi.org/10.1016/j.pdpdt.2020.101667 DOI: https://doi.org/10.1016/j.pdpdt.2020.101667
Mpourazanis G, Mpourazanis P, Stogiannidis G, et al. The effectiveness of photodynamic therapy and cryotherapy on patients with basal cell carcinoma: A systematic review and meta-analysis. Dermatol Ther 2020; 33(6): e13881. https://doi.org/10.1111/dth.13881 DOI: https://doi.org/10.1111/dth.13881
Rodrigues JA, Correia JH. Enhanced photodynamic therapy: a review of combined energy sources. Cells 2022; 11(24): 3995. https://doi.org/10.3390/cells11243995 DOI: https://doi.org/10.3390/cells11243995
Kessel D, Reiners JJ. Photodynamic therapy: autophagy and mitophagy, apoptosis and paraptosis. Autophagy 2020; 16(11): 2098-101. https://doi.org/10.1080/15548627.2020.1783823 DOI: https://doi.org/10.1080/15548627.2020.1783823
Kessel D. Death pathways associated with photodynamic therapy. Photochem Photobiol 2021; 97(5): 1101-103. https://doi.org/10.1111/php.13436 DOI: https://doi.org/10.1111/php.13436
Wang Y, Lin Y, Zhang HG, et al. A photodynamic therapy combined with topical 5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but less phototoxic for cancer. J Cancer Res Clin Oncol 2016; 142(4): 813-21. https://doi.org/10.1007/s00432-015-2066-3 DOI: https://doi.org/10.1007/s00432-015-2066-3
Zou Y, Zhao Y, Yu J, et al. Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. J Cosmet Dermatol 2016; 15(4): 374-82. https://doi.org/10.1111/jocd.12236 DOI: https://doi.org/10.1111/jocd.12236
Nguyen KP, Knuiman GJ, Blokx WAM, et al. Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial. J Dermatolog Treat 2019; 30(2): 194-99. https://doi.org/10.1080/09546634.2018.1484558 DOI: https://doi.org/10.1080/09546634.2018.1484558
Filonenko E, Kaprin A, Urlova A, et al. Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma. Photodiagnosis Photodyn Ther 2020; 30: 101644. https://doi.org/10.1016/j.pdpdt.2019.101644 DOI: https://doi.org/10.1016/j.pdpdt.2019.101644
Woźniak Z, Trzeciakowski W, Chlebicka I, et al. Photodynamic diagnosis and photodynamic therapy in basal cell carcinoma using a novel laser light source. Photodiagnosis Photodyn Ther 2020; 31: 101883. https://doi.org/10.1016/j.pdpdt.2020.101883 DOI: https://doi.org/10.1016/j.pdpdt.2020.101883
Gómez C, Cobos P, Alberdi E. Methyl aminolevulinate photodynamic therapy after partial debulking in the treatment of superficial and nodular basal cell carcinoma: 3-years follow-up. Photodiagnosis Photodyn Ther 2021; 33: 102176. https://doi.org/10.1016/j.pdpdt.2021.102176 DOI: https://doi.org/10.1016/j.pdpdt.2021.102176
Hellen R, Dhonncha EN, Havelin A, et al. An open-label prospective study to assess short incubation time white LED light photodynamic therapy in the treatment of superficial basal cell carcinoma. Photodermatol Photoimmunol Photomed 2022; 38(4): 322-27. https://doi.org/10.1111/phpp.12750 DOI: https://doi.org/10.1111/phpp.12750
Sukhova TE. The efficacy of photodynamic therapy for basal cell carcinoma with intralesional injection of radachlorine. Biomed Photonics 2015; 3: 24-8 (in Russian). https://doi.org/10.24931/2413-9432-2015-4-3-24-28 DOI: https://doi.org/10.24931/2413-9432-2015-4-3-24-28
Sukhova TE Intralesional injection of fotolon for photodynamic therapy of basal cell carcinoma. Biomed Photonics 2016; 5(1): 15-21 (in Russian). https://doi.org/10.24931/2413-9432-2016-5-1-15-21 DOI: https://doi.org/10.24931/2413-9432-2016-5-1-15-21
Kapinus VN, Kaplan MA, Yaroslavtseva-Isayeva EV, et al. Photodynamic therapy for head and neck basal cell skin cancer with additional interstitial laser irradiation. Biomed Photonics 2017; 6(4): 20-6 (in Russian). https://doi.org/10.24931/2413-9432-2017-6-4-20-26 DOI: https://doi.org/10.24931/2413-9432-2017-6-4-20-26
Kapinus VN, Kaplan MA, Yaroslavtseva-Isayeva EA, et al. Chlorine e6-photodynamic therapy basal cell carcinoma. Res Pract Med J 2021; 8(4): 33-43. https://doi.org/10.17709/2410-1893-2021-8-4-3 DOI: https://doi.org/10.17709/2410-1893-2021-8-4-3
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
